ELEVATE Blend for Women: Brain Fog, Anxiety, the Gut and What the Research Covers

The FDA's 2026 review found five small human studies in which BPC-157 was given to people. One was a 2024 single-arm pilot in which 12 women with interstitial cystitis were given BPC-157 injections into the bladder wall in one procedure; no adverse events or post-procedure complications were reported.

What it shows. That a small group of women tolerated a single bladder-wall procedure.

What it does not show. Anything about subcutaneous BPC-157, about ELEVATE, or about gut, mood or focus. It had no comparison group and was one procedure, not a course of treatment.

Semax's human evidence is Russian clinical work in stroke, chronic cerebrovascular disease and optic nerve disease using the intranasal product, plus a 14-person brain-imaging study after a single dose. Selank's is three small Russian trials (2008, 2014 and 2015) of 60 to 70 patients with anxiety-spectrum disorders, compared with benzodiazepines rather than placebo. None of these is reported by sex in the live research. The one sex-specific component study is the 2024 Semax experiment in the European Journal of Pharmacology, and it used male rats only, so it says nothing about women.

BPC-157's original and largest literature is rat work on protecting the stomach and intestinal lining against NSAID and alcohol damage. KPV's is mouse colitis work, much of it with KPV given in drinking water. KPV has no human trials of any kind.

Brain fog and low energy are among the commonest reasons women ask about ELEVATE. Iron deficiency and an underactive thyroid produce fatigue, brain fog and low mood, and both are far more common in women than in men: iron deficiency because of menstrual blood loss, and thyroid disease because autoimmune thyroiditis is heavily skewed toward women. Low B12 does the same. Poor sleep is the other big one. None of these responds to a peptide, and each is inexpensive to find. The live guidance is plain that fog during the menopausal transition is often driven by sleep disruption, thyroid disease or iron deficiency, and those should be excluded first. See peptides for brain fog and focus.

Anxiety and low mood that arrive in the forties without an obvious cause are often hormonal fluctuation plus sleep debt, and the live pages put screening first: thyroid, sleep, substances and existing care. Depression and anxiety disorders peak around the transition and warrant their own treatment. If you are on an SSRI, SNRI, benzodiazepine or antipsychotic, or have been diagnosed with panic disorder, bipolar disorder or major depression, that treatment comes first, and ELEVATE is at most an adjunct your prescriber may or may not agree to. Selank is not an antidepressant. More is in peptides for anxiety and mood.

None of the four components is hormone therapy, and none has been tested for hot flashes, night sweats, sleep, bone or any menopause outcome. If the transition is the driver, it belongs in the conversation with your physician rather than being treated around. Pepti does not prescribe menopausal hormone therapy.

The wider picture is in peptides for menopause and peptides for women.

There is no safety data for any ELEVATE component in pregnancy or lactation. The only reproductive data for BPC-157 is a rat teratogenicity study by intramuscular injection, and the FDA noted that nothing covered fertility, a full reproductive cycle or the subcutaneous route. ELEVATE is not used in pregnancy or while breastfeeding. If you are pregnant, trying to conceive or think you may be, tell your physician; if you become pregnant on treatment, stop and contact them the same day. See can you take peptides while pregnant and do peptides affect fertility.

None of the four components is a hormone or acts on the ovarian axis, and none is described as affecting hormonal contraception. No study has looked at that directly, so any cycle change on treatment is worth reporting, even if the transition or another cause is the likelier explanation.

KPV comes from alpha-MSH, the hormone that drives pigmentation, so women sometimes ask whether ELEVATE darkens skin, moles or melasma. It is not expected to: KPV keeps the anti-inflammatory signalling and drops the pigmentation effect, and Semax is described as devoid of its parent hormone's melanotropic activity. The peptide that does drive pigmentation, Melanotan II, is not in ELEVATE. Report any unexpected skin change.

Celiac disease, inflammatory bowel disease and H. pylori infection have established treatments and tests of their own. A diagnosed inflammatory bowel disease belongs with the specialist treating it, and immunosuppressants or biologics are raised specifically at intake. See peptides for gut health.